ABSTRACT
Introducción: la Ley Ricarte Soto (LRS) permite a pacientes con artritis reumatoide refractaria acceder a medicamentos biológicos. Sin embargo con esta regulación los pacientes inician éstos con actividad alta de enfermedad por un período prolongado, luego de recibir al menos 3 fármacos sintéticos. Previo a la implementación de esta ley no era necesario cumplir estos requisitos. Objetivos:comparar la respuesta a tratamiento lograda con el uso de medicamentos biológicos según niveles de actividad al inicio mediante la comparación de pacientes con biológicos antes y después de la LRS. Métodos: tomando datos del Programa de atención de pacientes con artritis reumatoide de la Red de Salud UC-Christus se compraró grupos de pacientes que accedieron a biológicos pre y post implementación de la LRS. Se analizó el cambio en DAS28 y la categorización de actividad de enfermedad según DAS28. Se realizó una regresión lineal evaluando edad, seropositividad y DAS28 pre tratamiento. Resultados: se encontró una diferencia significativa en el cambio de DAS28 a los 6 meses de tratamiento (p=0,02) y en la regresión solo con el DAS28 pre tratamiento (p=0,00). Dentro del grupo de pacientes que requirió cambio de biológico, los pacientes post ley iniciaron la terapia más activos y presentaban mayor persistencia de actividad severa a los 6 meses de tratamiento (11% vs 25%).Conclusiones: si bien el nivel de actividad al inicio no influyó en la respuesta a los 6 meses de tratamiento, si influyó en la persistencia de actividad severa en quienes requirieron cambio de biológico.
Introduction: Chilean regulations (Ley Ricarte Soto (RS) allow patients with refractory rheumatoid arthritis to have access to biological agents, but because of the requirements of the law, they spend a long period with active disease. Objectives: To compare the effective-ness of treatment with biological agents according to baseline disease activity by comparing subjects initiating biologics previous to and after ley RS. Methods: Using data from the rheumatoid arthritis clinic at Red Salud UC-Christus, we compared groups of patients who had access to biological agents before and after the implementation of the RS law. Change in DAS 28 was analyzed as well as disease activity categories according to DAS 28. We performed linear regression evaluating age, seropositivity, and baseline DAS28. Results: We found a significant difference in the DAS28 score delta at six months of treatment (p=0.02). In linear statistically significant association in the treatment response with the pre-treatment DAS28 (p=0.00), but in the group of patients that required more than one biological agent, the post-LRS group had a higher pre-treatment DAS28 and a higher rate of high disease activity (11% vs. 25%) after six months of treatment. Discussion: Although the baseline disease activity level did not influence the final response to treatment, it had an impact on the persistence of severe activity in patients that required more than one biologic agent
Subject(s)
Humans , Patients , Arthritis, Rheumatoid , Biological Products , Drug Therapy , Remission Induction , Immunosuppressive AgentsABSTRACT
ABSTRACT Background: The Health Assessment Questionnaire Disability Index (HAQDI) is one of the main instruments used to evaluate functional status in rheumatoid arthritis (RA). Aim: To assess the reliability and validity of the Spanish version of HAQDI in Chilean RA population. Materials and Methods: The questionnaire was applied to 98 patients with RA aged 44 ± 12 years (90% women). Reliability was assessed using Cronbach's alpha statistic for internal consistency. Construct validity was assessed by comparing total HAQDI value and eight HAQDI domains with multiple parameters of disease activity. Discriminant validity was evaluated by classifying disease activity in low, medium or high and evaluating HAQDI value in each category. Floor and ceiling effects were evaluated. To assess construct validity, principal components analysis was performed using varimax rotation. Results: There were no issues in the comprehensibility of the questionnaire. Mean HAQDI score was 1.57 ± 0.66. Standardized Cronbach's Alpha was 0.883. Correlations between Chilean HAQ domains had a p value less than 0.001, and values ranged from 0.317 to 0.597. Activity parameters, DAS 28 and CDAI were significantly correlated with HAQDI domains. Mean HAQDI values were 0.98 ± 0.59,1.45 ± 0.57, and 1.90 ± 0.56 for mild, moderate and severe disease activity. A principal components analysis identified two factors that accounted for 70.0% of total variability. Conclusions: This study shows that the Spanish version of HAQDI is reliable and valid and can be used in Chilean patients with RA.
Antecedentes: El Health Assessment Questionnaire Disability Index es uno de los principales instrumentos utilizados para evaluar incapacidad funcional en la artritis reumatoide (AR). Objetivo: Evaluar la fiabilidad y validez del HAQDI en la población chilena con AR. Material y Método: El cuestionario fue respondido por 98 pacientes con AR de 44 ± 12 años de edad (90% mujeres). La confiabilidad se evaluó usando la estadística alfa de Cronbach. La validez de constructo se evaluó comparando el valor total de HAQDI y de cada uno de sus dominios con múltiples parámetros de actividad de la enfermedad. La validez discriminante se evaluó clasificando la actividad de la enfermedad en bajo, medio o alto y evaluando el valor de HAQDI en cada categoría. Se determinaron efectos de piso y techo. Se realizó un análisis factorial utilizando rotación de varimax. Resultados: El valor promedio del HAQDI fue de 1,57 ± 0.66. El alfa estandarizado de Cronbach fue 0,883. Las correlaciones entre dominios de HAQDI tuvieron un valor p < 0,001 con valores entre 0,317 y 0,597. Los parámetros de actividad se correlacionaron significativamente con los dominios HAQDI. Se encontraron diferencias significativas entre el puntaje de HAQDI en relación con los grados de actividad de la enfermedad. Los valores medios de HAQDI fueron 0,98 ± 0,59, 1,45 ± 0,57 y 1,90 ± 0,56 para actividad leve, moderada y severa, respectivamente. El análisis de componentes principales identificó dos factores que representaron el 70.0% de la variabilidad total. Conclusiones: La versión española de HAQDI es confiable y válida en pacientes chilenos con AR.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Arthritis, Rheumatoid/physiopathology , Surveys and Questionnaires/standards , Disability Evaluation , Reference Values , Severity of Illness Index , Chile , Reproducibility of Results , Statistics, Nonparametric , LanguageABSTRACT
The classical manifestations of Behçet disease are mouth ana genital ulcers, cutaneous lesions ana ocular involvement. The central nervous system is affected in 5 to 59 percent of the cases, usually in the form of meningoencephalitis or sinus venous thrombosis. We report a 17-year-old femóle presenting with a two weeks history of progressive headache, nausea and blurred vision. An initial magnetic resonance was normal. Fifteen days later she was admitted to the hospital due to progression of visual impairment. Shegave a history of oral ulcers and arthralgias. A new magnetic resonance was normal. A lumbar puncture showed a cerebrospinal fluid with a protein concentration of 14 mg/dl, aglucose concentration of 64 mg/dl, 20fresh red blood cells and a pressure of 26 cm H(2)0. The diagnosis of a pseudotumor cerebri, secondary to Behçet disease was raised and the patient was treated with colchicine and acetazolamide. The evolution was torpid and an anterior uveitis was alsofound. After discharge, she continued with oral and genital ulcers and was treated with infliximab. Despite treatment, headache persists.
Subject(s)
Adolescent , Female , Humans , Behcet Syndrome/complications , Pseudotumor Cerebri/etiology , Acetazolamide/therapeutic use , Behcet Syndrome/diagnosis , Behcet Syndrome/drug therapy , Colchicine/therapeutic use , Pseudotumor Cerebri/diagnosis , Pseudotumor Cerebri/drug therapyABSTRACT
Coronary thrombosis as a manifestation of the antiphospholipid syndrome is very uncommon. We report a 25 year-old male without known cardiovascular risk factors that suffered an acute myocardial infarction as the initial manifestation of the antiphospholipid syndrome. His coronary angiogram demonstrated a single thrombotic lesion in the anterior descending artery without coronary atheromatosis. Anticardiolipin, anti B2 Glycoprotein I antibodies, and lupus anticoagulant were all positive. Besides the usual management of the coronary thrombosis, the patient was treated with permanent oral anticoagulation. Three months later, a CT coronary angiogram showed complete reperfusion of the involved artery.